Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients

Sheri Crow, Dong Chen, Carmelo Milano, William Thomas, Lyle Joyce, Valentino Piacentino, Riti Sharma, Jogin Wu, Gowthami Arepally, Dawn Bowles, Joseph Rogers, Nestor Villamizar-Ortiz

Research output: Contribution to journalArticle

229 Citations (Scopus)

Abstract

Background: Bleeding is a major cause of morbidity in recipients of continuous-flow left ventricular assist devices (CF-LVAD). A better understanding of the impact of CF-LVAD support on the hemostatic profile is necessary to establish better strategies for anticoagulation therapy and risk assessment for bleeding complications. A prospective multicenter study was conducted to characterize von Willebrand factor (vWF) profiles in patients undergoing CF-LVAD implantation. Methods: Blood samples were collected before and after CF-LVAD implantation from 37 patients between July 2008 and April 2009 at Duke University and the University of Minnesota. Blood samples were analyzed for vWF, platelet and collagen-binding ability. The presence of high-molecular-weight (HMW) vWF multimers were detected through gel electrophoresis, and deficiency was graded on a scale of 0 (normal) to 3 (severe loss). Results: All 37 patients exhibited significant loss of HMW vWF multimers within 30 days of CF-LVAD implantation. Ten of the 37 patients experienced bleeding complications after CF-LVAD placement. Conclusions: All CF-LVAD recipients had acquired von Willebrand syndrome after LVAD placement, demonstrated by reduced or absent HMW vWF multimer levels. However, not all recipients had bleeding complications. These findings suggest that loss of HMW vWF multimers alone cannot predict bleeding risk. Further refinement of laboratory techniques and a larger follow-up is required to identify risk factors for bleeding in CF-LVAD recipients.

Original languageEnglish (US)
Pages (from-to)1263-1269
Number of pages7
JournalAnnals of Thoracic Surgery
Volume90
Issue number4
DOIs
StatePublished - 2010

Fingerprint

Heart-Assist Devices
von Willebrand Factor
Hemorrhage
Molecular Weight
Hemostatics
Multicenter Studies
Electrophoresis
Collagen
Blood Platelets
Gels
Prospective Studies
Morbidity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Crow, S., Chen, D., Milano, C., Thomas, W., Joyce, L., Piacentino, V., ... Villamizar-Ortiz, N. (2010). Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Annals of Thoracic Surgery, 90(4), 1263-1269. https://doi.org/10.1016/j.athoracsur.2010.04.099

Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. / Crow, Sheri; Chen, Dong; Milano, Carmelo; Thomas, William; Joyce, Lyle; Piacentino, Valentino; Sharma, Riti; Wu, Jogin; Arepally, Gowthami; Bowles, Dawn; Rogers, Joseph; Villamizar-Ortiz, Nestor.

In: Annals of Thoracic Surgery, Vol. 90, No. 4, 2010, p. 1263-1269.

Research output: Contribution to journalArticle

Crow, S, Chen, D, Milano, C, Thomas, W, Joyce, L, Piacentino, V, Sharma, R, Wu, J, Arepally, G, Bowles, D, Rogers, J & Villamizar-Ortiz, N 2010, 'Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients', Annals of Thoracic Surgery, vol. 90, no. 4, pp. 1263-1269. https://doi.org/10.1016/j.athoracsur.2010.04.099
Crow, Sheri ; Chen, Dong ; Milano, Carmelo ; Thomas, William ; Joyce, Lyle ; Piacentino, Valentino ; Sharma, Riti ; Wu, Jogin ; Arepally, Gowthami ; Bowles, Dawn ; Rogers, Joseph ; Villamizar-Ortiz, Nestor. / Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. In: Annals of Thoracic Surgery. 2010 ; Vol. 90, No. 4. pp. 1263-1269.
@article{7a44cbc8bb8240348e47e74ec72c773f,
title = "Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients",
abstract = "Background: Bleeding is a major cause of morbidity in recipients of continuous-flow left ventricular assist devices (CF-LVAD). A better understanding of the impact of CF-LVAD support on the hemostatic profile is necessary to establish better strategies for anticoagulation therapy and risk assessment for bleeding complications. A prospective multicenter study was conducted to characterize von Willebrand factor (vWF) profiles in patients undergoing CF-LVAD implantation. Methods: Blood samples were collected before and after CF-LVAD implantation from 37 patients between July 2008 and April 2009 at Duke University and the University of Minnesota. Blood samples were analyzed for vWF, platelet and collagen-binding ability. The presence of high-molecular-weight (HMW) vWF multimers were detected through gel electrophoresis, and deficiency was graded on a scale of 0 (normal) to 3 (severe loss). Results: All 37 patients exhibited significant loss of HMW vWF multimers within 30 days of CF-LVAD implantation. Ten of the 37 patients experienced bleeding complications after CF-LVAD placement. Conclusions: All CF-LVAD recipients had acquired von Willebrand syndrome after LVAD placement, demonstrated by reduced or absent HMW vWF multimer levels. However, not all recipients had bleeding complications. These findings suggest that loss of HMW vWF multimers alone cannot predict bleeding risk. Further refinement of laboratory techniques and a larger follow-up is required to identify risk factors for bleeding in CF-LVAD recipients.",
author = "Sheri Crow and Dong Chen and Carmelo Milano and William Thomas and Lyle Joyce and Valentino Piacentino and Riti Sharma and Jogin Wu and Gowthami Arepally and Dawn Bowles and Joseph Rogers and Nestor Villamizar-Ortiz",
year = "2010",
doi = "10.1016/j.athoracsur.2010.04.099",
language = "English (US)",
volume = "90",
pages = "1263--1269",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients

AU - Crow, Sheri

AU - Chen, Dong

AU - Milano, Carmelo

AU - Thomas, William

AU - Joyce, Lyle

AU - Piacentino, Valentino

AU - Sharma, Riti

AU - Wu, Jogin

AU - Arepally, Gowthami

AU - Bowles, Dawn

AU - Rogers, Joseph

AU - Villamizar-Ortiz, Nestor

PY - 2010

Y1 - 2010

N2 - Background: Bleeding is a major cause of morbidity in recipients of continuous-flow left ventricular assist devices (CF-LVAD). A better understanding of the impact of CF-LVAD support on the hemostatic profile is necessary to establish better strategies for anticoagulation therapy and risk assessment for bleeding complications. A prospective multicenter study was conducted to characterize von Willebrand factor (vWF) profiles in patients undergoing CF-LVAD implantation. Methods: Blood samples were collected before and after CF-LVAD implantation from 37 patients between July 2008 and April 2009 at Duke University and the University of Minnesota. Blood samples were analyzed for vWF, platelet and collagen-binding ability. The presence of high-molecular-weight (HMW) vWF multimers were detected through gel electrophoresis, and deficiency was graded on a scale of 0 (normal) to 3 (severe loss). Results: All 37 patients exhibited significant loss of HMW vWF multimers within 30 days of CF-LVAD implantation. Ten of the 37 patients experienced bleeding complications after CF-LVAD placement. Conclusions: All CF-LVAD recipients had acquired von Willebrand syndrome after LVAD placement, demonstrated by reduced or absent HMW vWF multimer levels. However, not all recipients had bleeding complications. These findings suggest that loss of HMW vWF multimers alone cannot predict bleeding risk. Further refinement of laboratory techniques and a larger follow-up is required to identify risk factors for bleeding in CF-LVAD recipients.

AB - Background: Bleeding is a major cause of morbidity in recipients of continuous-flow left ventricular assist devices (CF-LVAD). A better understanding of the impact of CF-LVAD support on the hemostatic profile is necessary to establish better strategies for anticoagulation therapy and risk assessment for bleeding complications. A prospective multicenter study was conducted to characterize von Willebrand factor (vWF) profiles in patients undergoing CF-LVAD implantation. Methods: Blood samples were collected before and after CF-LVAD implantation from 37 patients between July 2008 and April 2009 at Duke University and the University of Minnesota. Blood samples were analyzed for vWF, platelet and collagen-binding ability. The presence of high-molecular-weight (HMW) vWF multimers were detected through gel electrophoresis, and deficiency was graded on a scale of 0 (normal) to 3 (severe loss). Results: All 37 patients exhibited significant loss of HMW vWF multimers within 30 days of CF-LVAD implantation. Ten of the 37 patients experienced bleeding complications after CF-LVAD placement. Conclusions: All CF-LVAD recipients had acquired von Willebrand syndrome after LVAD placement, demonstrated by reduced or absent HMW vWF multimer levels. However, not all recipients had bleeding complications. These findings suggest that loss of HMW vWF multimers alone cannot predict bleeding risk. Further refinement of laboratory techniques and a larger follow-up is required to identify risk factors for bleeding in CF-LVAD recipients.

UR - http://www.scopus.com/inward/record.url?scp=77957167053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957167053&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2010.04.099

DO - 10.1016/j.athoracsur.2010.04.099

M3 - Article

C2 - 20868825

AN - SCOPUS:77957167053

VL - 90

SP - 1263

EP - 1269

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 4

ER -